population, the estimated annual incidence is 0.54 per 100,000 people, rising to 2.3 to 10.2 per 100,000 in adults above age 50, according to the American Academy of Ophthalmology
P., Komninou, D., Leutzinger, Y., Kleinman, W., Orentreich, N., & Frei, B
Vivid or unusual dreams have been reported by many patients using tirzepatide
Monitoring recommendations during the early treatment period include regular self-monitoring of blood glucose, particularly for patients taking insulin or sulfonylureas, as dose adjustments of these medications may be necessary to prevent hypoglycemia
Researchers also evaluate changes in appetite, eating habits, portion control, metabolic health, body composition, gastrointestinal tolerance, physical activity, and overall well-being